Call Us : 07894 123 533

BSTP Webinars

Registration to take part in some of these webinars is free with the dial in details provided at least one week prior to the date of the webinar.

For confidentiality reasons if you are not a member of the BSTP or any other recognised pathology society but, you are a veterinary student or resident, or an early career pathologist you will be required to provide written confirmation of your status from your Head of Department (on headed paper) before you are sent the dial in information.


Where available, recordings of webinars are available in the members only area of the BSTP website.

BSTP/STP - Carcinogenesis Webinar - 27th October 2020

BSTP/STP - Respiratory Webinar - 10th November 2020

BSTP/STP - Pathology of Mice With Humanised Immune Systems - 8th December 2020

BSTP/STP - The Fog Dissipates: Insight Into Pulmonary Effects of Vaping - 25th May 2021


Webinar Dates: 

BSTP/STP Webinars 2021

28th September 2021 - BSTP/STP Webinar:  A Pathologist Perspective on the Non-Clinical Safety Assessment of GalNAc-conjugated RNAi Therapeutics
10:30 AM EDT, 3:30 PM GMT/ 4:30 PM CET

A BSTP webinar - in collaboration with the Society of Toxicological Pathology (STP) to be held on Tuesday 28th September 2021, at 10:30 AM Eastern Daylight Time (New York, GMT-04:00), 3:30 PM GMT Time (London, GMT+01:00), and the duration of the webinar will be up to 1 hour.

A Pathologist Perspective on the Non-Clinical Safety Assessment of GalNAc-conjugated RNAi Therapeutics
By Drs. Arlin Rogers and Wendell Davis (Alnylam Pharmaceuticals)

Abstract: The discovery and elucidation of the mechanism of RNA interference (RNAi) by Fire and Mello, and the subsequent work by Tuschi to demonstrate mammalian RNAi has spurred the field of small interfering RNA (siRNA)-based therapeutics for the treatment of a wide range of human disorders. siRNA-based therapeutics harness a highly conserved natural RNAi mechanism whereby short, 20-25 nucleotide-long, double-stranded RNAs catalyze the sequence-specific downregulation of a disease-causing messenger RNA (mRNA).  

The field of siRNA-based therapeutics has recently matured with the approvals of ONPATTROTM and GIVLAARITM for the treatment of hereditary transthyretin-mediated amyloidosis and acute hepatic porphyria, respectively. Many other candidate siRNAs are currently in various stages of clinical development across several therapeutic areas.

In this webinar, we will discuss the science behind siRNA-based therapeutics, some features of a typical development package and the pathology findings frequently observed in toxicology studies. In addition, we will provide some insights into the process of identifying development candidates.

.

2nd November 2021 - Alessio Ciulli (Dundee Uni) and Kevin Moreau/Kimberly Maratea (AZ) – Topic: PROteolysis Targeting Chimeras (PROTACs) (intro, safety, pathology)

Keep checking here for more details or contact the BSTP Secretariat - bstpoffice@aol.com


 

BSTP/IATP Webinars 2021 (area: preclinical model translation)

Autumn 2021 - Provisional topic - NASH

Keep checking here for more details or contact the BSTP Secretariat - bstpoffice@aol.com


BSTP/EHF Webinars 2021 (area: histology/ technology innovation/cool science meets pathology)

Keep checking here for more details or contact the BSTP Secretariat - bstpoffice@aol.com